Hospitals balk as CMS doubles down on price transparency

Shannon Muchmore | May 12, 2020

Dive Brief:

Dive Insight:

The American Hospital Association, which is suing HHS for earlier price transparency efforts, did not mince words when responding to the draft Monday evening.

“We are very disappointed that CMS continues down the unlawful path of requiring hospitals to disclose privately negotiated contract terms,” the group said in a statement. “The disclosure of privately negotiated rates will not further CMS’s goal of paying market rates that reflect the cost of delivering care. These rates take into account any number of unique circumstances between a private payer and a hospital and simply are not relevant for fixing Fee-for-Service Medicare reimbursement.”

In arguments last week in the U.S. District Court for the District of Columbia, AHA argued the mandates to disclose secret negotiated prices violate the First Amendment, as the data are protected proprietary information.

CMS had said it would update its proposal for the hospital star ratings methodology in the draft rule, but the agency will now hold off until future rulemaking because of pressures from regulatory adaptions to the COVID-19 pandemic. Hospitals have said the ratings are flawed and don’t provide accurate and useful information on care quality.

In an update to its inpatient quality reporting program, CMS is proposing to progressively increase the number of quarters hospitals are required to report electronic clinical quality measures, starting with two quarters in 2021 and reaching four quarters for 2023 and beyond.

The rule also proposes publicly reporting the eCQM data for the first time, beginning with calendar year 2021.

CMS had hinted at the CAR-T reimbursement change earlier. Currently, payment is under a category for stem cell and bone marrow transplants with a new technology add-on payment and is likely to leave hospitals at a loss.

In the draft payment rule, the agency also proposes 24 new applications for add-on payments and expanding the pathway for antimicrobial products that FDA has designated as a Qualified Infectious Disease Product to include products approved under FDA’s Limited Population Pathway for Antibacterial and Antifungal Drugs.

CMS Administrator Seema Verma said on Twitter the change will create a more streamlined process for certain antimicrobial products, “speeding up beneficiary access to critical therapies they need.”

The IPPS also outlines uncompensated care payments to disproportionate share hospitals for FY 2021, which it estimates will be $7.8 billion, down about $500 million from the previous fiscal year.

Comments on the proposed rule are due July 10.

Source: Healthcare Dive